Windkracht schreef op 13 april 2018 08:46:
Onderstaande in het jaarverslag, vind ik positief. Geeft aan dat er mogelijkheden zijn om Atir101 als veel breder 'platform'in te kunnen gaan zetten!
If approved, we intend to market ATIR101 in Europe and North America through an internal commercial organization. We believe
we will not require a large commercial infrastructure as the transplant community has a relatively small number of key opinion
leaders, or KOLs, and is concentrated among relatively few transplant centers. For example, there are only approximately 70
stem cell transplant centers in France, Germany, Italy, Spain and the United Kingdom. In addition, the ongoing Phase III study
is allowing us to build relationships within the transplant community. We have started building our own commercial, medical
affairs, and supply chain infrastructure, including our own manufacturing facility in The Netherlands.In the future, we could expand usage of our ATIR platform by performing additional studies in the pediatric population, inherited
blood disorders (e.g., thalassemia or sickle cell anemia), inherited immune disorders (e.g., severe combined immunodeficiency)
and autoimmune disease (e.g., multiple sclerosis or lupus), and by developing ATIR101 as an adjunctive therapy to other HSCTprotocols, such as the PTCy protocol or an a/ß T-cell depleted HSCT. In addition, we aim to expand to other regions, such as
China, where haploidentical HSCT is often the only available treatment due to small family sizes and lack of donor registries.